Engineering of tandem bispecific IL-7 receptor agonist antibody promoting selective T cell expansion
Protein Engineering, Design and Selection · 09.01.2026 · 39
DOI: 10.1093/protein/gzag017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, online erschienen am 08.07.2026. Verfasst von Jun-Kook Park und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Republic of Korea. Hauptthemen laut MEDLINE: Antibodies, Bispecific, T-Lymphocytes, Protein Engineering, Receptors, Interleukin-7. Die Arbeit nennt 73 Literaturangaben. Gefördert von: National Research Foundation of Korea, Basic Science Research Program through the National Research Foundation of Korea (NRF), Ministry of Education.
Abstract (Originalsprache)
Interleukin-7 (IL-7) is indispensable for T cell development and homeostasis, and clinical studies have demonstrated its ability to restore T cell numbers in lymphopenic conditions. However, the therapeutic application of IL-7 has been limited by its short half-life and potential immunogenicity of recombinant variants. To overcome these challenges, we engineered a fully human tandem bispecific antibody, TB4, that functions as a potent IL-7 receptor agonist by cis-targeting IL-7 receptor alpha (IL-7Rα) and the common γ chain (γc). The tetravalent tandem scFv-Fc architecture, coupled with optimized linker length, conferred markedly enhanced binding affinity and avidity compared to the knobs-into-holes bispecific format, with domain orientation designed to limit unintended γc binding. At the cellular level, TB4 engaged both receptor subunits and exhibited reduced internalization dynamics, features that are likely to contribute to the sustained STAT5 phosphorylation observed in primary human T cells. Functionally, TB4 supported long-term T cell survival and expansion, but selectively promoted the expansion of CD4+ memory subsets, especially effector memory cells re-expressing CD45RA populations, in contrast to the broader effects of native IL-7. Transcriptomic profiling further revealed that while both TB4 and IL-7 activated proliferative gene programs, TB4 uniquely drove an antiviral and innate immune signature. Collectively, these findings establish TB4 as a next-generation IL-7R agonist antibody with a differentiated mechanism of action and potential as a precision immunomodulator that can selectively expand and reprogram T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Republic of Korea.
- Bio Research Dept., Ahngook pharm, Gyeonggi-do 13840, Republic of Korea.
- DGIST-ETH Microrobotics Research Center, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Republic of Korea.
- Department of Biomedical Engineering, Institute for Applied Life Sciences, University of Massachusetts Amherst, 240 Thatcher Road, Amherst, MA 01003, USA.
- New Biology Research Center, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Republic of Korea.
ORCID-Profile: Kyungmoo Yea
Förderung
- National Research Foundation of Korea
- Basic Science Research Program through the National Research Foundation of Korea (NRF)
- Ministry of Education
- Korea Drug Development Fund funded by the Ministry of Science
- Ministry of Trade, Industry and Energy
- Ministry of Health and Welfare
- Ahngook Pharm. Co., Ltd., Republic of Korea
- DGIST R&D Program funded by the Ministry of Science and ICT (24-KUJoint-04)
Zitieren
APA
Park, J. K., Jung, I., Lee, S., Kim, J., Shin, S., Shin, J., Noh, S., Kwon, D., Nam, C., Kim, H., Choi, H., & Yea, K. (2026). Engineering of tandem bispecific IL-7 receptor agonist antibody promoting selective T cell expansion. Protein Engineering, Design and Selection, 39. https://doi.org/10.1093/protein/gzag017
Vancouver
Park JK, Jung I, Lee S, Kim J, Shin S, Shin J, et al. Engineering of tandem bispecific IL-7 receptor agonist antibody promoting selective T cell expansion. Protein Engineering, Design and Selection. 2026;39. doi:10.1093/protein/gzag017
BibTeX
@article{Park2026,
author = {Park, Jun-Kook and Jung, Inseong and Lee, Seunghyun and Kim, Jisuk and Shin, Sanghee and Shin, Jiwon and Noh, Soojeong and Kwon, Dahye and Nam, Chaerin and Kim, Hyunwook and Choi, Hongsoo and Yea, Kyungmoo},
title = {Engineering of tandem bispecific IL-7 receptor agonist antibody promoting selective T cell expansion},
journal = {Protein Engineering, Design and Selection},
year = {2026},
volume = {39},
doi = {10.1093/protein/gzag017}
}
EUVIMED